TY - JOUR T1 - Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study JF - European Respiratory Journal JO - Eur Respir J VL - 42 IS - Suppl 57 SP - P3635 AU - Donald A. Mahler AU - Marc Decramer AU - Anthony D'Urzo AU - Heinrich Worth AU - Tracy White AU - Vijay Alagappan AU - Hungta Chen AU - Karoly Kulich AU - Nicola Gallagher AU - Donald Banerji Y1 - 2013/09/01 UR - http://erj.ersjournals.com/content/42/Suppl_57/P3635.abstract N2 - IntroductionDyspnea, the most distressing symptom experienced by COPD patients, is not always adequately relieved by bronchodilator monotherapy. The BLAZE study evaluated the superiority of QVA149, a dual bronchodilator combining the long-acting β2-agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium, versus placebo (PB) and tiotropium (TIO) for improvement in direct patient-reported dyspnea as assessed by the innovative self-administered computerized baseline and transition dyspnea index (SAC-BDI/TDI).MethodIn this multicenter, blinded, placebo-controlled, 3-period, crossover study, patients ≥40yrs were randomized to once-daily QVA149 110/50µg, TIO 18µg, or PB. Improvements were assessed by the total TDI score after 6wks.Results247 patients (mean age 62.8yrs; FEV1 post-bronchodilator 56.1% predicted) were randomized; 77.3% completed the study. Patient-reported SAC-TDI total score was significantly improved with QVA149 compared to PB (p<0.001) and TIO (p=0.021). Least squares mean treatment differences between QVA-PB, QVA149-TIO and TIO-PB were 1.37, 0.49 and 0.88, respectively. The percentage of patients achieving ≥1 point improvement in SAC-TDI score was significantly higher with QVA149 (QVA149 34.7%, TIO 24.9%, PB 18.1%) compared to PB (odds ratio [OR] 2.65; p<0.001) and TIO (OR 1.66; p=0.037). The percentage of patients showing any adverse event with QVA149 (35.0%) was similar to TIO (35.5%) and slightly lower than PB (39.4%).ConclusionDual bronchodilation with QVA149 provided statistically superior improvements in patient reported breathlessness compared to tiotropium and placebo. ER -